Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma
Multiple myeloma (MM) is a very heterogeneous disease with multiple symptoms and clinical manifestations. MM affects mainly elderly patients and is difficult to manage in the presence of comorbidities, polypharmacy, frailty and adverse events of disease-targeted drugs. The rapid changes in MM treatm...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1282300/full |
| _version_ | 1797249256442036224 |
|---|---|
| author | Catarina Geraldes Catarina Geraldes Catarina Geraldes Catarina Geraldes Catarina Geraldes Adriana Roque Adriana Roque Ana Bela Sarmento-Ribeiro Ana Bela Sarmento-Ribeiro Ana Bela Sarmento-Ribeiro Ana Bela Sarmento-Ribeiro Ana Bela Sarmento-Ribeiro Manuel Neves Alina Ionita Rita Gerivaz Ana Tomé Sofia Afonso Sofia Afonso Maria Pedro Silveira Patrícia Sousa Rui Bergantim Rui Bergantim Rui Bergantim Cristina João Cristina João |
| author_facet | Catarina Geraldes Catarina Geraldes Catarina Geraldes Catarina Geraldes Catarina Geraldes Adriana Roque Adriana Roque Ana Bela Sarmento-Ribeiro Ana Bela Sarmento-Ribeiro Ana Bela Sarmento-Ribeiro Ana Bela Sarmento-Ribeiro Ana Bela Sarmento-Ribeiro Manuel Neves Alina Ionita Rita Gerivaz Ana Tomé Sofia Afonso Sofia Afonso Maria Pedro Silveira Patrícia Sousa Rui Bergantim Rui Bergantim Rui Bergantim Cristina João Cristina João |
| author_sort | Catarina Geraldes |
| collection | DOAJ |
| description | Multiple myeloma (MM) is a very heterogeneous disease with multiple symptoms and clinical manifestations. MM affects mainly elderly patients and is difficult to manage in the presence of comorbidities, polypharmacy, frailty and adverse events of disease-targeted drugs. The rapid changes in MM treatment resulting from constant innovations in this area, together with the introduction of numerous new drugs with distinct mechanisms of action and toxicity profiles, have led to an increased complexity in the therapeutic decision-making and patient management processes. The prolonged exposure to novel agents, sometimes in combination with conventional therapies, makes this management even more challenging. A careful balance between treatment efficacy and its tolerability should be considered for every patient. During treatment, a close monitoring of comorbidities, disease-related manifestations and treatment side effects is recommended, as well as a proactive approach, with reinforcement of information and patient awareness for the early recognition of adverse events, allowing prompt therapeutic adjustments. In this review, we discuss various issues that must be considered in the treatment of MM patients, while giving practical guidance for monitoring, prevention and management of myeloma-related manifestations and treatment-related toxicities. |
| first_indexed | 2024-04-24T20:27:36Z |
| format | Article |
| id | doaj.art-051ee31b6b64476ca027ed20cc61d7ea |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-24T20:27:36Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-051ee31b6b64476ca027ed20cc61d7ea2024-03-22T04:34:57ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-03-011410.3389/fonc.2024.12823001282300Practical management of disease-related manifestations and drug toxicities in patients with multiple myelomaCatarina Geraldes0Catarina Geraldes1Catarina Geraldes2Catarina Geraldes3Catarina Geraldes4Adriana Roque5Adriana Roque6Ana Bela Sarmento-Ribeiro7Ana Bela Sarmento-Ribeiro8Ana Bela Sarmento-Ribeiro9Ana Bela Sarmento-Ribeiro10Ana Bela Sarmento-Ribeiro11Manuel Neves12Alina Ionita13Rita Gerivaz14Ana Tomé15Sofia Afonso16Sofia Afonso17Maria Pedro Silveira18Patrícia Sousa19Rui Bergantim20Rui Bergantim21Rui Bergantim22Cristina João23Cristina João24Serviço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra, Coimbra, PortugalFaculty of Medicine, University of Coimbra, Coimbra, PortugalCoimbra Institute for Clinical and Biomedical Research, Faculty of Medicine, University of Coimbra, Coimbra, PortugalCenter for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, PortugalClinical Academic Center of Coimbra (CACC), Coimbra, PortugalServiço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra, Coimbra, PortugalInstitute of Physiology, Faculty of Medicine, University of Coimbra, Coimbra, PortugalServiço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra, Coimbra, PortugalFaculty of Medicine, University of Coimbra, Coimbra, PortugalCoimbra Institute for Clinical and Biomedical Research, Faculty of Medicine, University of Coimbra, Coimbra, PortugalCenter for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, PortugalClinical Academic Center of Coimbra (CACC), Coimbra, PortugalHemato-Oncology Unit, Champalimaud Foundation, Lisboa, PortugalHematology Department, Portuguese Institute of Oncology Francisco Gentil, Lisboa, PortugalServiço de Hemato-oncologia, Hospital Garcia de Orta, Lisboa, PortugalServiço de Hemato-oncologia, Hospital Garcia de Orta, Lisboa, Portugal0Serviço de Hematologia Clínica, Centro Hospitalar Universitário Cova da Beira, Covilhã, Portugal1Faculdade de Ciências da Saúde, Universidade da Beira Interior, Covilhã, Portugal2Serviço de Imuno-Hemoterapia, Hospital Prof. Doutor Fernando Fonseca, EPE, Amadora, Portugal2Serviço de Imuno-Hemoterapia, Hospital Prof. Doutor Fernando Fonseca, EPE, Amadora, Portugal4Serviço de Hematologia Clínica, Centro Hospitalar Universitário de São João (CHUSJ), Porto, Portugal5Instituto de Investigação e Inovaçáo em Saúde, Universidade do Porto, Porto, Portugal6Institute of Pathology and Molecular Immunology, Abel Salazar Institute of Biomedical Sciences, University of Porto, Porto, PortugalHemato-Oncology Unit, Champalimaud Foundation, Lisboa, Portugal7NOVA Medical School, Universidade Nova de Lisboa, Lisboa, PortugalMultiple myeloma (MM) is a very heterogeneous disease with multiple symptoms and clinical manifestations. MM affects mainly elderly patients and is difficult to manage in the presence of comorbidities, polypharmacy, frailty and adverse events of disease-targeted drugs. The rapid changes in MM treatment resulting from constant innovations in this area, together with the introduction of numerous new drugs with distinct mechanisms of action and toxicity profiles, have led to an increased complexity in the therapeutic decision-making and patient management processes. The prolonged exposure to novel agents, sometimes in combination with conventional therapies, makes this management even more challenging. A careful balance between treatment efficacy and its tolerability should be considered for every patient. During treatment, a close monitoring of comorbidities, disease-related manifestations and treatment side effects is recommended, as well as a proactive approach, with reinforcement of information and patient awareness for the early recognition of adverse events, allowing prompt therapeutic adjustments. In this review, we discuss various issues that must be considered in the treatment of MM patients, while giving practical guidance for monitoring, prevention and management of myeloma-related manifestations and treatment-related toxicities.https://www.frontiersin.org/articles/10.3389/fonc.2024.1282300/fulldelivery of health carecancer managementanticancer drug toxicitiesmultiple myelomareal life practical considerationsmyeloma-related manifestations |
| spellingShingle | Catarina Geraldes Catarina Geraldes Catarina Geraldes Catarina Geraldes Catarina Geraldes Adriana Roque Adriana Roque Ana Bela Sarmento-Ribeiro Ana Bela Sarmento-Ribeiro Ana Bela Sarmento-Ribeiro Ana Bela Sarmento-Ribeiro Ana Bela Sarmento-Ribeiro Manuel Neves Alina Ionita Rita Gerivaz Ana Tomé Sofia Afonso Sofia Afonso Maria Pedro Silveira Patrícia Sousa Rui Bergantim Rui Bergantim Rui Bergantim Cristina João Cristina João Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma Frontiers in Oncology delivery of health care cancer management anticancer drug toxicities multiple myeloma real life practical considerations myeloma-related manifestations |
| title | Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma |
| title_full | Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma |
| title_fullStr | Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma |
| title_full_unstemmed | Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma |
| title_short | Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma |
| title_sort | practical management of disease related manifestations and drug toxicities in patients with multiple myeloma |
| topic | delivery of health care cancer management anticancer drug toxicities multiple myeloma real life practical considerations myeloma-related manifestations |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1282300/full |
| work_keys_str_mv | AT catarinageraldes practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT catarinageraldes practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT catarinageraldes practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT catarinageraldes practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT catarinageraldes practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT adrianaroque practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT adrianaroque practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT anabelasarmentoribeiro practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT anabelasarmentoribeiro practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT anabelasarmentoribeiro practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT anabelasarmentoribeiro practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT anabelasarmentoribeiro practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT manuelneves practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT alinaionita practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT ritagerivaz practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT anatome practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT sofiaafonso practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT sofiaafonso practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT mariapedrosilveira practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT patriciasousa practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT ruibergantim practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT ruibergantim practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT ruibergantim practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT cristinajoao practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma AT cristinajoao practicalmanagementofdiseaserelatedmanifestationsanddrugtoxicitiesinpatientswithmultiplemyeloma |